Articles related to OBESITY/WEIGHT MANAGEMENT

This pooled analysis provides robust evidence that low-dose glucocorticoids in RA treatment result in modest weight gain but do not elevate blood pressure. Consider these findings in your risk-benefit discussions with patients.

The updated prescribing guidelines for Wegovy (semaglutide) offer new maintenance dosing options for adults, reflecting recent research findings.

The recent systematic review comparing obesity management drugs highlights semaglutide and phentermine/topiramate as the most effective in weight loss and waist circumference reduction at 12 months. Explore the full study to understand the comparative efficacy and safety of these medications in obesity treatment.

The potential shortage of Saxenda (liraglutide) through 2023 underscores the importance of monitoring the availability of this weight management drug. Physicians should be aware of this situation and consider alternative options if necessary.

With varying incidence rates of paradoxical adipose hypertrophy (PAH) and increasing reports of disfigurement, CoolSculpting’s non-invasive fat reduction procedure warrants careful examination. Physicians are encouraged to delve into the research and counsel patients thoroughly on potential risks and alternative approaches.

Orforglipron is a novel once-daily oral GLP-1 receptor agonist that has been shown to be effective in reducing weight in adults with obesity or overweight. Further studies are needed to establish whether the health benefits seen with injectable GLP-1 receptor agonists are shared by orforglipron.